

**Happy Holidays**

As we approach 2020, we reflect on the progress Dignitana has made in the past year. Our new device, DigniCap Delta, is a major leap forward in scalp cooling technology. Many more patients can now be offered this important therapy option as Dignitana continues to change the lives of cancer patients every day. Thank you for your support and trust in 2019. We look forward to an exciting year of growth in 2020.

DigniCap in the News

Swedish business magazine Affärsvärlden featured Dignitana in an article on the 50 fastest growing tech companies in Sweden. The article is based on a report by Deloitte. Dignitana ranked # 39 - one out of four companies representing the health and life science industry. Read full list here: fast50.se

Redeye Coverage of Dignitana

December 4, Redeye released their initial coverage analysis on *Dignitana - Growth Not About to Cool Off*. Read the full report here: redeye.se/research/584959/dignitana-growth-not-about-cool

DigniCap Delta Update

The rollout of DigniCap Delta continues as scheduled and the new device has been well received by doctors, nurses and patients. While we are also adding new sites, Dignitana is currently focusing on upgrading existing customers to the new device and high usage sites are the priority. As of December 2019 we are well ahead of the distribution plan.

Shareholder Question:

How long does it take for a new facility to become profitable?

After a contract is signed, installation and training are scheduled. This can take several weeks depending on the schedule of the facility. Once the equipment is installed one of our clinical team members will typically spend 2-3 days to train several groups of nurses and meet with doctors. This ensures that the facility is fully informed and feels comfortable with DigniCap. Often, the first DigniCap patient is also treated at this time. From there, the doctors and nurses begin to offer DigniCap to patients, but because the frequency of chemotherapy regimens varies it can take 3 to 6 months before the machine is utilized on a regular basis. A facility becomes "profitable" based on several factors including number of new patients, total number of treatments, and other financial terms in the contract, which are then balanced against Dignitana expenses related to supporting the new facility.

Q3 Interim Report Published

The 2019 Q3 Interim Report was published on 19 November 2019. The same day Dignitana arranged a tele conference as well as participated in Redeye Life Science Day 2019. The presentation by CEO William Cronin can be viewed here: redeye.se/live/lis-day-2019

Year End Report Scheduled

Dignitana's 2019 Year End Report will be published on 25 February 2020. Financial reports posted here: dignitana.com/investor-relations/financial-reports/

Clinical Study Update

Our partner Konica Minolta manages the ongoing clinical trial at Beijing University Cancer Hospital, and we are expecting preliminary results in 2020. The trial will provide valuable insights on an exclusively Asian population as Dignitana prepares to commercialize DigniCap throughout Asia.

We are initiating additional clinical studies in the first half of 2020 to demonstrate the superiority of DigniCap and to expand our clinical indication to a wider group of patients.

Dignitana Exhibitions

In November, Dignitana exhibited at the Chemotherapy Foundation Symposium in New York, USA, the Academy of Oncology Nurse & Patient Navigators in Nashville, USA, and the United Kingdom Oncology Nursing Society in Telford, UK.

The San Antonio Breast Cancer Symposium in San Antonio, Texas, USA is happening at the time of this publication. Kicking off 2020, Dignitana and Middle East distributor Tesla Medical Solutions will exhibit at Arab Health, January 27-30 in Dubai, UAE.

DigniCap Availability

The DigniCap Scalp Cooling System is now available at medical centers in 30 states and in 38 countries. New locations since the last newsletter include:

- Northwestern Memorial Healthcare - Chicago, Illinois, U.S.
- Cancer Treatment Centers of America - Newnan, Georgia, U.S.
- Florida Cancer Specialists - Stuart, Florida, U.S.
- Providence Health Queen of the Valley - Napa, California, U.S.
- Advent Health Shawnee Mission - Overland Park, Kansas, U.S.
- Edward Elmhurst Health - Elmhurst, Illinois, U.S.

Dignitana AB, Traktorgränden 3, SE-226 60 Lund Sweden

Per MAR guidelines, company announcements are posted at www.dignitana.se and distributed to Nasdaq First North Growth Market, Nordic News Agencies, and financial websites [Subscribe here](mailto:investorrelations@dignitana.com) to receive this newsletter by email or email investorrelations@dignitana.com